Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1545232 | 0.82 | GBA1 (0.50) | GBA1SIGMAR1ABL1RIN1OPRD1 | |
| SCHEMBL1535090 | 0.78 | GBA1 (0.59) | GBA1MAPT | |
| SCHEMBL19281632 | 0.78 | MAPT (0.51) | MAPT | |
| SCHEMBL20659898 | 0.78 | S1PR5 (0.44) | MAPT | |
| SCHEMBL17631636 | 0.78 | MAPT (0.51) | MAPT | |
| SCHEMBL3545125 | 0.78 | GBA1 (0.42) | GBA1SIGMAR1OPRD1 | |
| SCHEMBL5839370 | 0.76 | DRD2 (0.40) | MAPT | |
| SCHEMBL18922664 | 0.75 | GBA1 (0.82) | GBA1MAPT | |
| SCHEMBL22554885 | 0.75 | GBA1 (0.82) | GBA1MAPT | |
| SCHEMBL21403832 | 0.75 | GBA1 (0.82) | GBA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732461-B2 | (4S)-4-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-3-fluoro-4-hydroxy-4,5-dihydro-7H-pyrrolo[3,2,1-de]-1,5-naphthyridin-7-one, used in the treatment of bacterial infections caused by a wide range of organisms including both gramnegative and grampositive bacteria | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20090137568-A1 | Tryclic Nitrogen Containing Compounds and their Use as Antibacterials | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137568-A1 | Tryclic Nitrogen Containing Compounds and their Use as Antibacterials | NRDC, NACA, ASNS | GBA1 3817/4885MAPT 1460/4885SIGMAR1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.